Q: What is Kisunla used for?

Kisunla is used to treat Alzheimer's disease .

Q: How does Kisunla work?

Targeting Amyloid Plaques In people with Alzheimer's disease, a protein called amyloid-beta clumps together to form plaques in the brain. These plaques are believed to interfere with how brain cells communicate and contribute to the loss of cognitive function over time. How the Medication Works Kisunla is a monoclonal antibody, which is a type of protein designed in a laboratory to recognize and bind to specific targets in the body. This medication specifically targets the amyloid-beta plaques that have already formed in the brain. Once Kisunla attaches to these plaques, it helps the body's immune system identify and remove them. Slowing Disease Progression By reducing the buildup of amyloid plaques, Kisunla is intended to slow the decline of memory and thinking skills. It also aims to help patients maintain their ability to perform daily activities for a longer period. The treatment is specifically for individuals in the early stages of Alzheimer's disease, including those with mild cognitive impairment or mild dementia. Unlike some other treatments, Kisunla may be stopped once brain imaging shows that a significant amount of plaque has been cleared from the brain.

Q: What are the active ingredients in Kisunla?

The active ingredient in Kisunla is donanemab .

Q: What are the side effects of Kisunla?

Common side effects of Kisunla may include: infusion-related reactions headache nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is Kisunla?

Kisunla belongs to the SGLT2 inhibitor drug class.

Q: What is the dosage of Kisunla and how do I take it?

How Kisunla is Given Kisunla is delivered directly into a vein through an intravenous (IV) infusion. These treatments are performed by a healthcare provider in a clinical setting, such as a doctor's office or infusion center. Each infusion session typically lasts about 30 minutes. The standard schedule for Kisunla is one infusion every four weeks. Your healthcare provider will monitor you during the infusion and for a period afterward to check for any immediate reactions to the medication. Duration of Treatment Unlike many other medications for chronic conditions, Kisunla may not be a lifelong treatment. Your doctor will use brain imaging, such as PET scans, to monitor the levels of amyloid plaques in your brain. If these plaques reach a sufficiently low level, your doctor may decide to stop the treatments. Missed Doses If you miss an appointment for your infusion, contact your healthcare provider right away to reschedule. Generally, the missed dose should be given as soon as possible. After receiving the missed dose, your next infusion will typically be scheduled for four weeks later to maintain the correct timing between treatments.

Q: Is Kisunla safe during pregnancy and breastfeeding?

Pregnancy It is unknown whether Kisunla can cause harm to an unborn baby. Because Alzheimer's disease primarily affects older adults, there is no information from clinical trials about the drug's effects on pregnant individuals. If you are pregnant or planning to become pregnant, you should discuss the potential risks and benefits of this treatment with your healthcare provider. Breastfeeding It is not known if Kisunla passes into human breast milk or if it has any effect on a nursing infant. Because many medications can be excreted in breast milk, it is important to talk to your doctor about the risks and the best way to feed your baby while receiving this medication.

Q: What forms and strengths does Kisunla come in?

Available Forms Kisunla is supplied in the following form: Intravenous Injection: A sterile, clear to opalescent, colorless to slightly yellow solution provided in a single-dose vial. This medication is administered as an infusion into a vein. It is provided as a concentrate that must be diluted by a healthcare professional before it is given to the patient.

Q: What is the FDA approval status of Kisunla?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Kisunla in July 2024. It is indicated for patients with early symptomatic Alzheimer’s disease, which includes individuals with mild cognitive impairment or those in the mild dementia stage of the disease. Treatment is appropriate only for patients with confirmed amyloid pathology in the brain. Boxed Warning Kisunla includes a Boxed Warning regarding Amyloid-Related Imaging Abnormalities (ARIA). ARIA most commonly presents as temporary swelling in areas of the brain (ARIA-E) or small spots of bleeding in or on the surface of the brain (ARIA-H). While ARIA often does not cause symptoms, it can lead to serious or life-threatening events. Symptoms may include headache, confusion, dizziness, vision changes, or seizures. Monitoring and Safety Requirements MRI Monitoring: Healthcare providers must obtain a baseline brain MRI before starting treatment. Periodic follow-up MRIs are required during treatment to monitor for the development of ARIA. ApoE ε4 Genotyping: Testing for ApoE ε4 status should be performed prior to initiation. Patients who are homozygous for the ApoE ε4 allele have a higher observed incidence of ARIA compared to heterozygotes and non-carriers. Infusion Reactions: The FDA labeling includes warnings for infusion-related reactions, which can include flu-like symptoms, nausea, vomiting, and blood pressure changes. Clinical Trial Basis The approval was supported by data from the TRAILBLAZER-ALZ 2 clinical trial, a double-blind, placebo-controlled study. The trial demonstrated that Kisunla significantly slowed clinical and functional decline in patients with early symptomatic Alzheimer’s disease compared to those receiving a placebo.

Question 1

What is Kisunla?

Accepted Answer

Kisunla is a monoclonal antibody designed to identify and attach to amyloid-beta plaques, which are protein clusters that build up in the brain. By targeting these plaques, the medication helps the immune system clear them away.

The primary goal of this therapy is to address the underlying biological changes associated with cognitive decline. By reducing the amyloid burden in the brain, the treatment aims to slow the progression of the disease.

Question 2

What is Kisunla used for?

Accepted Answer

Kisunla is used to treat Alzheimer's disease.

Question 3

How does Kisunla work?

Accepted Answer

Targeting Amyloid Plaques

In people with Alzheimer's disease, a protein called amyloid-beta clumps together to form plaques in the brain. These plaques are believed to interfere with how brain cells communicate and contribute to the loss of cognitive function over time.

How the Medication Works

Kisunla is a monoclonal antibody, which is a type of protein designed in a laboratory to recognize and bind to specific targets in the body. This medication specifically targets the amyloid-beta plaques that have already formed in the brain. Once Kisunla attaches to these plaques, it helps the body's immune system identify and remove them.

Slowing Disease Progression

By reducing the buildup of amyloid plaques, Kisunla is intended to slow the decline of memory and thinking skills. It also aims to help patients maintain their ability to perform daily activities for a longer period. The treatment is specifically for individuals in the early stages of Alzheimer's disease, including those with mild cognitive impairment or mild dementia.

Unlike some other treatments, Kisunla may be stopped once brain imaging shows that a significant amount of plaque has been cleared from the brain.

Question 4

What are the active ingredients in Kisunla?

Accepted Answer

The active ingredient in Kisunla is donanemab.

Question 5

What are the side effects of Kisunla?

Accepted Answer

Common side effects of Kisunla may include:

infusion-related reactions
headache
nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Kisunla?

Accepted Answer

Kisunla belongs to the SGLT2 inhibitor drug class.

Question 7

What is the dosage of Kisunla and how do I take it?

Accepted Answer

How Kisunla is Given

Kisunla is delivered directly into a vein through an intravenous (IV) infusion. These treatments are performed by a healthcare provider in a clinical setting, such as a doctor's office or infusion center. Each infusion session typically lasts about 30 minutes.

The standard schedule for Kisunla is one infusion every four weeks. Your healthcare provider will monitor you during the infusion and for a period afterward to check for any immediate reactions to the medication.

Duration of Treatment

Unlike many other medications for chronic conditions, Kisunla may not be a lifelong treatment. Your doctor will use brain imaging, such as PET scans, to monitor the levels of amyloid plaques in your brain. If these plaques reach a sufficiently low level, your doctor may decide to stop the treatments.

Missed Doses

If you miss an appointment for your infusion, contact your healthcare provider right away to reschedule. Generally, the missed dose should be given as soon as possible. After receiving the missed dose, your next infusion will typically be scheduled for four weeks later to maintain the correct timing between treatments.

Question 8

Is Kisunla safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is unknown whether Kisunla can cause harm to an unborn baby. Because Alzheimer's disease primarily affects older adults, there is no information from clinical trials about the drug's effects on pregnant individuals. If you are pregnant or planning to become pregnant, you should discuss the potential risks and benefits of this treatment with your healthcare provider.

Breastfeeding

It is not known if Kisunla passes into human breast milk or if it has any effect on a nursing infant. Because many medications can be excreted in breast milk, it is important to talk to your doctor about the risks and the best way to feed your baby while receiving this medication.

Question 9

What forms and strengths does Kisunla come in?

Accepted Answer

Available Forms

Kisunla is supplied in the following form:

Intravenous Injection: A sterile, clear to opalescent, colorless to slightly yellow solution provided in a single-dose vial.

This medication is administered as an infusion into a vein. It is provided as a concentrate that must be diluted by a healthcare professional before it is given to the patient.

Question 10

What is the FDA approval status of Kisunla?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Kisunla in July 2024. It is indicated for patients with early symptomatic Alzheimer’s disease, which includes individuals with mild cognitive impairment or those in the mild dementia stage of the disease. Treatment is appropriate only for patients with confirmed amyloid pathology in the brain.

Boxed Warning

Kisunla includes a Boxed Warning regarding Amyloid-Related Imaging Abnormalities (ARIA). ARIA most commonly presents as temporary swelling in areas of the brain (ARIA-E) or small spots of bleeding in or on the surface of the brain (ARIA-H). While ARIA often does not cause symptoms, it can lead to serious or life-threatening events. Symptoms may include headache, confusion, dizziness, vision changes, or seizures.

Monitoring and Safety Requirements

MRI Monitoring: Healthcare providers must obtain a baseline brain MRI before starting treatment. Periodic follow-up MRIs are required during treatment to monitor for the development of ARIA.
ApoE ε4 Genotyping: Testing for ApoE ε4 status should be performed prior to initiation. Patients who are homozygous for the ApoE ε4 allele have a higher observed incidence of ARIA compared to heterozygotes and non-carriers.
Infusion Reactions: The FDA labeling includes warnings for infusion-related reactions, which can include flu-like symptoms, nausea, vomiting, and blood pressure changes.

Clinical Trial Basis

The approval was supported by data from the TRAILBLAZER-ALZ 2 clinical trial, a double-blind, placebo-controlled study. The trial demonstrated that Kisunla significantly slowed clinical and functional decline in patients with early symptomatic Alzheimer’s disease compared to those receiving a placebo.

Question 11

What should I know about Kisunla and withdrawal?

Accepted Answer

Withdrawal and Discontinuation

There is currently no evidence that Kisunla (donanemab-azbt) causes withdrawal symptoms or physical dependence. Monoclonal antibodies used for Alzheimer's disease do not typically lead to physical cravings or illness when the medication is discontinued.

A unique aspect of Kisunla treatment is that it is not necessarily intended to be lifelong. Clinical trials showed that treatment could be stopped once amyloid plaques in the brain reached very low levels, as measured by PET scans. Your healthcare provider will monitor your progress and determine when it is appropriate to pause or end the infusions.

If you miss a dose or decide to stop treatment, you should contact your healthcare provider. While stopping the drug does not cause a withdrawal syndrome, it will stop the medication's effect on clearing amyloid plaques from the brain.

Kisunla

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Kisunla

Hospitals.net Disclosure